EXPANDING NILOTINIB ACCESS IN CLINICAL TRIALS (ENACT) STUDY IN ADULT PATIENTS WITH IMATINIB-RESISTANT OR-INTOLERANT CHRONIC MYELOID LEUKEMIA (CML): FINAL SAFETY ANALYSIS OF 117 CHINESE CML PATIENTS

被引：0
|
作者：
Shen, Z. [1 ]
Huang, X. [2 ]
Meng, F. [3 ]
Wang, J. [4 ,5 ,8 ]
Liu, T. [6 ]
Hu, J. [7 ]
Wang, J. [4 ,5 ,8 ]
Zhao, Y. [9 ]
Woodman, R. [8 ]
Zou, P. [10 ]
机构：
[1] Shanghai Jiao Tong Univ, Sch Med, Shanghai 200030, Peoples R China
[2] Beijing Univ, Beijing 100871, Peoples R China
[3] Nanfang Med Univ, Guangzhou, Guangdong, Peoples R China
[4] Chinese Acad Med Sci, Tianjin, Peoples R China
[5] Peking Union Med Coll, Tianjin, Peoples R China
[6] Sichuan Univ, Chengdu 610064, Peoples R China
[7] Fujian Med Univ, Affiliated Union Hosp, Fuzhou, Fujian, Peoples R China
[8] Novartis Pharmaceut, E Hanover, NJ USA
[9] Novartis Pharmaceut Co Ltd, Beijing, Peoples R China
[10] Huazhong Univ Sci & Technol, Tongji Med Coll, Wuhan 430074, Peoples R China
来源：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2009年 / 94卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
0865
引用
收藏
页码：348 / 349
页数：2
相关论文
共 50 条
  • [41] A phase II study of nilotinib administered to imatinib resistant or intolerant patients with chronic myelogenous leukemia (CML) in accelerated phase (AP)
    le Coutre, P.
    Gattermann, N.
    Hochhaus, A.
    Larson, R.
    Weitzman, A.
    Haque, A.
    Giles, F.
    O'Brien, S. G.
    Kantarjian, H. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [42] Detection of new mutations in patients (pts) with imatinib-resistant chronic myeloid leukemia in chronic phase (CML-CP) treated with nilotinib.
    Hochhaus, A.
    Saglio, A.
    Kantarjian, H.
    Haque, A.
    Shou, Y.
    Woodman, R. C.
    Hughes, T. P.
    Radich, J. P.
    Martinelli, G.
    Kim, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [43] Nilotinib in patients with imatinib-resistant or -intolerant chronic myelogenous leukaemia in chronic phase (CML-CP): updated phase 2 results
    Clark, R.
    Kantarjian, H. M.
    Giles, F. J.
    Hochhaus, A.
    Bhalla, K. N.
    Ossenkoppele, G.
    Gattermann, N.
    Haque, A.
    Gallagher, N.
    Baccarani, M.
    le Coutre, P.
    BRITISH JOURNAL OF HAEMATOLOGY, 2008, 141 : 57 - 58
  • [44] Nilotinib in Imatinib-Resistant or -Intolerant Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): 48-Month Follow-up Results of a Phase 2 Study
    le Coutre, Philipp D.
    Giles, Francis J.
    Pinilla-Ibarz, Javier
    Larson, Richard A.
    Gattermann, Norbert
    Ottmann, Oliver G.
    Hochhaus, Andreas
    Radich, Jerald P.
    Saglio, Giuseppe
    Hughes, Timothy P.
    Martinelli, Giovanni
    Kim, Dong-Wook
    Branford, Susan
    Mueller, Martin C.
    Shou, Yaping
    Novick, Steven
    Fan, Xiaolin
    Cortes, Jorge E.
    Baccarani, Michele
    Kantarjian, Hagop M.
    BLOOD, 2011, 118 (21) : 1610 - 1610
  • [45] A phase II study of nilotinib a novel tyrosine kinase inhibitor administered to imatinib-resistant or intolerant patients with chronic myelogenous leukemia (CML) in accelerated phase (AP).
    Kantarjian, Hagop M.
    Gattermann, Norbert
    Hochhaus, Andreas
    Larson, Richard
    Rafferty, Teresa
    Weitzman, Aaron
    Haque, Ariful
    Giles, Francis
    O'Brien, S. G.
    le Coutre, Philipp
    BLOOD, 2006, 108 (11) : 615A - 615A
  • [46] Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase
    Cortes, J.
    Kim, D-W
    Raffoux, E.
    Martinelli, G.
    Ritchie, E.
    Roy, L.
    Coutre, S.
    Corm, S.
    Hamerschlak, N.
    Tang, J-L
    Hochhaus, A.
    Khoury, H. J.
    Bruemmendorf, T. H.
    Michallet, M.
    Rege-Cambrin, G.
    Gambacorti-Passerini, C.
    Radich, J. P.
    Ernst, T.
    Zhu, C.
    Van Tornout, J. M. A.
    Talpaz, M.
    LEUKEMIA, 2008, 22 (12) : 2176 - 2183
  • [47] Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase
    J Cortes
    D-W Kim
    E Raffoux
    G Martinelli
    E Ritchie
    L Roy
    S Coutre
    S Corm
    N Hamerschlak
    J-L Tang
    A Hochhaus
    H J Khoury
    T H Brümmendorf
    M Michallet
    G Rege-Cambrin
    C Gambacorti-Passerini
    J P Radich
    T Ernst
    C Zhu
    J M A Van Tornout
    M Talpaz
    Leukemia, 2008, 22 : 2176 - 2183
  • [48] Dasatinib Induces Significant Hematologic and Cytogenetic Responses in Patients with Imatinib-resistant or-intolerant Chronic Myeloid Leukemia in Accelerated Phase
    Bajpai, Jyoti
    INDIAN JOURNAL OF MEDICAL AND PAEDIATRIC ONCOLOGY, 2008, 29 (04) : 23 - U24
  • [49] Nilotinib Efficacy According to Baseline BCR-ABL Mutations in Patients with Imatinib-Resistant Chronic Myeloid Leukemia in Chronic Phase (CML-CP)
    Hochhaus, Andreas
    Kim, Dong-Wook
    Martinelli, Giovanni
    Hughes, Timothy P.
    Soverini, Simona
    Branford, Susan
    Muller, Martin C.
    Erben, Philipp
    Haque, Ariful
    Shou, Yaping
    Saglio, Giuseppe
    Radich, Jerald P.
    BLOOD, 2008, 112 (11) : 1103 - 1104
  • [50] PATTERNS OF TREATMENT OF CHRONIC MYELOID LEUKEMIA (CML) PATIENTS RESISTANT OR INTOLERANT TO IMATINIB IN PUBLICH HEALTH INSTITUTIONS IN MEXICO
    Hernandez-Rivera, G.
    Aguayo-Gonzalez, A.
    Cantu-Rodriguez, O. G.
    Cervera, E.
    Gomez-Almaguer, D.
    Gutierrez-Aguirre, C. H.
    Lopez-Hernandez, M.
    Martinez-Banos, D.
    Oropeza, P.
    Rico, E.
    Juarez-Garcia, A.
    Vargas-Valencia, J.
    VALUE IN HEALTH, 2011, 14 (07) : A537 - A537
12345